Two Convenient Submission Methods

We offer two streamlined pathways for manuscript submission, designed to accommodate different researcher preferences and manuscript types. Choose the method that best fits your workflow:

HIV/AIDS Research We Publish

JCRHAP welcomes diverse clinical research contributions that advance our understanding of HIV/AIDS prevention, diagnosis, treatment, and care. Our scope encompasses the full spectrum of HIV clinical research:

Article Types We Accept

We publish a comprehensive range of manuscript types to accommodate different research methodologies and findings in HIV/AIDS clinical research:

Pre-Submission Checklist

Ensure your manuscript is complete and properly formatted before submission. This checklist covers the essential components required for all HIV/AIDS clinical research submissions:

Peer Review Timeline

We are committed to providing rapid, rigorous peer review by experts in HIV/AIDS clinical research. Our transparent timeline ensures you know what to expect at each stage:

Our Peer Review Process

Initial Screening (3 days): Our editorial team conducts a rapid assessment of manuscript completeness, scope alignment, and ethical compliance. We check for proper ethics approval, clinical trial registration, and adherence to reporting guidelines (CONSORT, STROBE, PRISMA, CARE).

Expert Review (21 days): Manuscripts are reviewed by at least two independent experts in HIV/AIDS clinical research, selected based on their specific expertise in your study area (e.g., ART efficacy, PrEP implementation, HIV diagnostics). Reviewers evaluate scientific rigor, clinical relevance, methodological soundness, and contribution to HIV/AIDS care.

Editorial Decision (28 days): Based on reviewer recommendations, the handling editor makes one of four decisions: Accept, Minor Revisions, Major Revisions, or Reject. You receive detailed reviewer comments and clear guidance on required revisions.

Revision Process: If revisions are requested, you'll have access to specific reviewer comments through the ManuscriptZone portal. We encourage point-by-point responses to reviewer concerns. Revised manuscripts undergo expedited re-review (14 days) focusing on how you addressed the comments.

Fast-Track Option: Urgent public health communications, outbreak reports, or time-sensitive findings may qualify for our 10-day fast-track review process. Contact the editorial office to request fast-track consideration.

Manuscript Preparation Guidelines

Structure Your HIV/AIDS Clinical Research Manuscript

Follow this standard structure for original research articles and clinical trials:

Title Page: Include a concise, informative title (maximum 150 characters), full author names with affiliations, corresponding author contact information, word count, and keywords (5-8 terms from MeSH or HIV/AIDS-specific terminology).

Abstract (250 words maximum): Structure your abstract with clear sections:

• Background: State the research question and rationale
• Methods: Describe study design, population, and key methods
• Results: Present main findings with key statistics
• Conclusions: State clinical implications and significance

Introduction: Provide context for your research, review relevant literature, identify gaps in current knowledge, and clearly state your research objectives or hypotheses. For clinical trials, reference the trial protocol and registration.

Methods: Describe your study design, setting, population, eligibility criteria, interventions (if applicable), outcome measures, sample size calculation, statistical methods, and ethical approvals. Include clinical trial registration number for interventional studies. Follow CONSORT, STROBE, or other relevant reporting guidelines.

Results: Present findings in logical sequence, use tables and figures effectively, report all pre-specified outcomes, include confidence intervals and p-values, and describe participant flow (enrollment, allocation, follow-up, analysis).

Discussion: Interpret your findings in context of existing literature, discuss clinical implications for HIV/AIDS care, acknowledge study limitations, suggest directions for future research, and avoid overstating conclusions.

Conclusions: Provide a concise summary of key findings and their clinical significance for HIV/AIDS prevention, treatment, or care.

Special Considerations for HIV/AIDS Research

Patient Privacy: Ensure all patient data is de-identified. Do not include patient names, initials, hospital numbers, or identifiable images without explicit written consent.

Stigma-Sensitive Language: Use person-first language ("people living with HIV" not "HIV patients"), avoid stigmatizing terms, and be culturally sensitive in describing populations and behaviors.

Drug Nomenclature: Use generic drug names (e.g., "tenofovir disoproxil fumarate" not "Viread") with brand names in parentheses on first mention. Follow WHO or INN conventions.

Laboratory Values: Report CD4 counts, viral loads, and other laboratory values with units (cells/μL, copies/mL). Specify assay methods and detection limits.